- Home
- VRAX vs TXMD Comparison
VRAX vs TXMD Comparison
Compare VRAX & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- TXMD
- Stock Information
- Founded
- VRAX 2013
- TXMD 2008
- Country
- VRAX United Kingdom
- TXMD United States
- Employees
- VRAX N/A
- TXMD N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- TXMD Health Care
- Exchange
- VRAX Nasdaq
- TXMD Nasdaq
- Market Cap
- VRAX 4.7M
- TXMD 12.8M
- IPO Year
- VRAX 2022
- TXMD N/A
- Fundamental
- Price
- VRAX $0.84
- TXMD $1.13
- Analyst Decision
- VRAX Strong Buy
- TXMD
- Analyst Count
- VRAX 1
- TXMD 0
- Target Price
- VRAX $3.00
- TXMD N/A
- AVG Volume (30 Days)
- VRAX 40.3K
- TXMD 60.3K
- Earning Date
- VRAX 02-05-2025
- TXMD 08-11-2025
- Dividend Yield
- VRAX N/A
- TXMD N/A
- EPS Growth
- VRAX N/A
- TXMD N/A
- EPS
- VRAX N/A
- TXMD N/A
- Revenue
- VRAX $84,872.00
- TXMD $1,841,000.00
- Revenue This Year
- VRAX $5,169.18
- TXMD $427.09
- Revenue Next Year
- VRAX $66.97
- TXMD N/A
- P/E Ratio
- VRAX N/A
- TXMD N/A
- Revenue Growth
- VRAX 7.03
- TXMD 53.55
- 52 Week Low
- VRAX $0.74
- TXMD $0.70
- 52 Week High
- VRAX $9.00
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- VRAX 35.04
- TXMD 44.02
- Support Level
- VRAX $0.74
- TXMD $1.07
- Resistance Level
- VRAX $0.86
- TXMD $1.21
- Average True Range (ATR)
- VRAX 0.07
- TXMD 0.09
- MACD
- VRAX -0.00
- TXMD 0.00
- Stochastic Oscillator
- VRAX 16.87
- TXMD 54.68
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.